Celgene

NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing price May 22, 2020
Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
Jon C. Ogg
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...
Chris Lange
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Chris Lange
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The September 30 short interest data has been compared with the previous report, and short interest in...
Chris Lange
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Many mergers have been announced or have closed, but just seven recent and pending deals have transformed how analysts and investors alike are having to view corporate America.
Jon C. Ogg
The August 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Chris Lange
Both Amgen and Celgene shares made a handy gain on Monday after it was announced that the companies had made an agreement in relation to Celgene’s merger with Bristol-Myers Squibb.
Chris Lange
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Jon C. Ogg
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Chris Lange
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Chris Lange
Jounce Therapeutics shares jumped on Wednesday after the company announced an update on its strategic collaboration with Celgene. This collaboration was originally established in July of 2016.
Chris Lange
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most...
Chris Lange
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange